Edgewise Therapeutics Overview
Edgewise Therapeutics Target Price
Analysts' 12-month price predictions for EWTX.
Get informed when a big investor buys or sells
+ FollowShare Price
$39.73
Average Target Price
$50.80
27.9% upside
27.9% upside10 analysts in the last 4 months
High: $66 | Low: $32
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-07-09 | Oppenheimer | $51 | 28.4% upside |  |
| 2026-07-06 | GuggenheimDebjit Chattopadhyay | $51 | 28.4% upside | |
| 2026-06-17 | RBC Capital | $59 | 48.5% upside | |
| 2026-06-17 | Goldman SachsPaul Choi | $32 |  19.5% downside | |
| 2026-06-16 | Leerink Partners | $52 | 30.9% upside | |
| 2026-06-02 | H.C. Wainwright | $45 | 13.3% upside | |
| 2026-06-02 | RBC CapitalLeonid Timashev | $48 | 20.8% upside | |
| 2026-06-01 | Raymond JamesMartin Auster | $66 | 66.1% upside | |
| 2026-06-01 | WedbushLaura Chico | $52 | 30.9% upside | |
| 2026-05-06 | Truist Financial | $52 | 30.9% upside | |
| 2026-03-10 | Raymond JamesMartin Auster | $46 | 15.8% upside | |
| 2026-02-26 | Evercore ISICory Kasimov | $45 | 13.3% upside | |
| 2026-02-26 | Stifel NicolausJames Condulis | $25 | 37.1% downside | |
| 2025-09-24 | Goldman Sachs | $20 | 49.7% downside | |
| 2025-03-07 | Scotiabank | $50 | 25.8% upside | |
| 2024-12-05 | Truist FinancialSrikripa Devarakonda | $50 | 25.8% upside | |
| 2024-10-11 | Piper SandlerYasmeen Rahimi | $51 | 28.4% upside | |
| 2024-09-20 | RBC CapitalLeonid Timashev | $42 | 5.7% upside | |
| 2024-09-19 | Leerink PartnersJoseph Schwartz | $42 | 5.7% upside | |
| 2024-07-01 | Piper SandlerYasmeen Rahimi | $48 | 20.8% upside | |